MAYNE PHARMA GROUP LIMITED — Director's Dealing 2020

Aug 31, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Scott Anthony Richards
Date of last notice	9 Jan 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest	Solium Nominees (Australia) Pty Ltd <Bare Allocated A/C> as
(including registered holder)	nominee for Scott Richards (1)
Note: Provide details of the circumstancesgiving rise to the relevant interest.	HSBC Nominees (Australia) Limited as nominee for Scott AnthonyRichards (2)
	HSBC Nominees (Australia) Limited as nominee for Scott Anthony
	Richards & Susan Marie Richards (3)
Date of change	31 Aug 2020
No. of securities held prior to	22,779,411 Ordinary Shares pursuant to Executive Share Loan
change	Scheme (1)
	3,862,906 Ordinary Shares (2)
	1,722,463 Ordinary Shares (3)
	2,555,805 Performance Rights pursuant to Performance Right and
	Option Plan
Class	Ordinary Shares
Number acquired	Nil
Number disposed	2,553,496
Value/Consideration	Not Applicable. Forfeit of employee loan shares pursuant to the
Note: If consideration is non-cash, provide	Executive Share Loan Scheme.
details and estimated valuation

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held afterchange	20,225,915 Ordinary Shares pursuant to Executive Share LoanScheme (1)3,862,906 Ordinary Shares (2) 1,722,463 Ordinary Shares (3)2,555,805 Performance Rights pursuant to Performance Right andOption Plan
Nature of changeExample: on-market trade, off-market trade,exercise of options, issue of securities underdividend reinvestment plan, participation inbuy-back	Forfeit of employee loan shares pursuant to the Executive ShareLoan Scheme.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contractsdetailed above traded during a+closed period whereprior written clearance was required?	N/a
If so, was prior written clearance provided to allowthe trade toproceed during thisperiod?	N/a
If prior written clearance was provided, on whatdate was thisprovided?	N/a

• See chapter 19 for defined terms.

Appendix 3Y Page 2